Sugar Maple Asset Management LLC Invests $740,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Sugar Maple Asset Management LLC acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 11,000 shares of the company's stock, valued at approximately $740,000.

A number of other large investors have also modified their holdings of the company. Arizona State Retirement System increased its holdings in TransMedics Group by 1.9% in the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock worth $603,000 after acquiring an additional 184 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its holdings in TransMedics Group by 7.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock worth $294,000 after acquiring an additional 317 shares in the last quarter. NBC Securities Inc. purchased a new stake in TransMedics Group in the 1st quarter worth $25,000. Atlas Capital Advisors Inc. purchased a new stake in TransMedics Group in the 4th quarter worth $31,000. Finally, Alliancebernstein L.P. increased its holdings in TransMedics Group by 1.2% in the 4th quarter. Alliancebernstein L.P. now owns 40,572 shares of the company's stock worth $2,530,000 after acquiring an additional 500 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Insider Activity

In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the transaction, the director now owns 732 shares of the company's stock, valued at $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David Weill sold 732 shares of the company's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the transaction, the director now directly owns 12,134 shares in the company, valued at $1,503,159.92. The trade was a 5.69% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,732 shares of company stock valued at $1,416,710. 7.00% of the stock is currently owned by insiders.

TransMedics Group Trading Up 2.6%

Shares of TMDX stock traded up $3.46 on Friday, hitting $139.05. 783,703 shares of the stock traded hands, compared to its average volume of 1,362,820. The firm's 50-day moving average price is $101.54 and its two-hundred day moving average price is $80.29. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market capitalization of $4.70 billion, a PE ratio of 147.93 and a beta of 2.10. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's revenue was up 48.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.35 EPS. As a group, analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Oppenheimer boosted their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 3rd. Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of "Moderate Buy" and a consensus price target of $125.11.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.